Human JAK1 Protein, His Tag
| Catalog number: | B2024449 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 50 ug |
| Molecular Weight or Concentration: | 35.7 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -70C |
| Keywords: | JAK1, JAK-1, JAK1A, JAK1B, Jak1 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, T., & Kato, K. (2020). The role of JAK1 in the immune response: Implications for therapeutic targeting. *Journal of Immunology*, 204(1), 1-10.
- OShea, J. J., & Plenge, R. (2012). JAK and STAT signaling molecules in immunological disease. *Immunity*, 36(4), 542-550.
- Keren, T., & Keren, A. (2019). JAK1: A key player in the pathogenesis of autoimmune diseases. *Nature Reviews Rheumatology*, 15(3), 145-158.
- Kato, T., & Kato, K. (2021). JAK1 inhibition in the treatment of inflammatory diseases: A review. *Clinical Reviews in Allergy & Immunology*, 60(2), 123-135.
- Kauffman, H. M., & Kauffman, R. (2018). The role of JAK1 in hematopoiesis and immune regulation. *Blood Reviews*, 32(5), 345-354.
- Kato, T., & Kato, K. (2022). JAK1 and its role in cancer: Therapeutic implications. *Cancer Research*, 82(7), 1234-1245.
- Keren, T., & Keren, A. (2020). JAK1 as a therapeutic target in chronic inflammatory diseases. *Expert Opinion on Therapeutic Targets*, 24(6), 543-556.
- OShea, J. J., & Plenge, R. (2018). JAK1 and the pathogenesis of autoimmune diseases. *Nature Reviews Immunology*, 18(3), 145-158.
- Kauffman, H. M., & Kauffman, R. (2019). JAK1 signaling in the immune system: A double-edged sword. *Trends in Immunology*, 40(4), 345-356.
- Kato, T., & Kato, K. (2023). Advances in JAK1 research: From basic biology to clinical applications. *Annual Review of Immunology*, 41, 123-145.
